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Purpose: This study investigates the effects of triamcinolone acetonide (TA) on retinal endothelial cells in vitro and
explores the potential vascular toxic effect of TA injected into the vitreous cavity of rats in vivo.
Methods: Subconfluent endothelial cells were treated with either 0.1 mg/ml or 1 mg/ml TA in 1% ethanol. Control cells
were either untreated or exposed to 1% ethanol. Cell viability was evaluated at 24 h, 72 h, and five days using the
tetrazolium 3-(4,5-dimethylthiazol-2-yl)-2,5 phenyltetrazolium bromide test (MTT) and lactate dehydrogenase (LDH)
assays. Cell proliferation was evaluated by 5-bromo-2-deoxyuridine (BrdU) test. Apoptosis was evaluated by terminal
deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL assay), annexin-binding, and caspase 3 activation.
Caspase–independent cell deaths were investigated by immunohistochemistry using antibodies against apoptosis inducing
factor (AIF), cytochrome C, microtubule-associated protein (MAP)-light chain 3 (MAP-LC3), and Leukocyte Elastase
Inhibitor/Leukocyte Elastase Inhibitor-derived DNase II (LEI/L-DNase II). In vivo, semithin and ultrathin structure
analysis and vascular casts were performed to examine TA-induced changes of the choroidal vasculature. In addition,
outer segments phagocytosis assay on primary retinal pigment epithelium (RPE) cells was performed to assess
cyclooxygenase (COX-2) and vascular endothelial growth factor (VEGF) mRNAs upregulation with or without TA.
Results: The inhibitory effect of TA on cell proliferation could not explain the significant reduction in cell viability.
Indeed, TA induced a time-dependent reduction of bovine retinal endothelial cells viability. Annexin-binding positive
cells were observed. Cytochrome C was not released from mitochondria. L-DNase II was found translocated to the nucleus,
meaning that LEI was changed into L-DNase II. AIF was found nuclearized in some cells. LC3 labeling showed the
absence of autophagic vesicles. No autophagy or caspase dependent apoptosis was identified. At 1 mg/ml TA induced
necrosis while exposure to lower concentrations for 3 to 5 days induced caspase independent apoptosis involving AIF and
LEI/L-DNase II. In vivo, semithin and ultrathin structure analysis and vascular casts revealed that TA mostly affected the
choroidal vasculature with a reduction of choroidal thickness and increased the avascular areas of the choriocapillaries.
Experiments performed on primary RPE cells showed that TA downregulates the basal expression of COX-2 and VEGF
and inhibits the outer segments (OS)-dependent COX-2 induction but not the OS-dependent VEGF induction.
Conclusions: This study demonstrates for the first time that glucocorticoids exert direct toxic effect on endothelial cells
through caspase-independent cell death mechanisms. The choroidal changes observed after TA intravitreous injection
may have important implications regarding the safety profile of TA use in human eyes.
Glucocorticoids are commonly used in the treatment of
ocular pathologies associated with vascular leakage, vessels
abnormalities, and ocular neovascularization. Intravitreous
injections of Triamcinolone Acetonide (TA) are currently
used for the treatment of macular edema [1,2]. They induce a
dramatic reduction of macular thickness but this is
inconsistently correlated with long-term functional recovery.
When used for the treatment of choroidal neovascularizations
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associated with Age-related Macular Degeneration (AMD) or
other ocular neovascularisations, TA decreases the vascular
leakage on the short-term [3]. However, its long-term effect
on visual acuity remains controversial [4-6]. For the treatment
of retinal neovascularization, TA has been used mostly in
combination with other antivascular strategies [7,8]. On
capillary eyelid hemangiomas, glucocorticoids seem to have
beneficial effects through a reduction in the size of the
vascular lesion [9].
The vascular effects of TA have been confirmed in animal
models of choroidal (CNV) and retinal neovascularization. In
the rat model of laser-induced CNV, TA not only decreased
fluorescein angiography (FA) leakage [10,11], but it also
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reduced the CNV membrane diameter and thickness [11,12],
and transiently inhibited CNV formation [13]. In the rat model
of retinopathy of prematurity, TA reduced the retinal
neovascularization in a dose-dependent manner [14-17] and
reduced the vascular leakage [16].
In vitro, TA has been shown to downregulate the
expression of tumor necrosis factor α, vascular endothelial
growth factor (VEGF), interleukin 1, and matrix
metalloproteinases, and subsequently influence
neovascularization [16]. TA has also been reported to have
direct effects on endothelial cells through an antiproliferative
effect [17] and a reduction in the interferon-induced
permeability of human choroidal endothelial cells [18].
Beside their known effects on vascular permeability, the
in vivo antiangiogenic/angiostatic activity of corticosteroids
results from many factors, including their anti-inflammatory
activities. However, it remains unknown if TA can directly
induce vascular endothelial cell death. In this paper, we
investigated the mechanisms of the effects of TA on retinal
endothelial cells in vitro and in the rat retinal and choroidal
vascularization in vivo.
METHODS
Reagents: All culture reagents were obtained from Gibco
(New York, NY). Corticosteroids were purchased from Sigma
(Saint-Quentin-Fallavier, France) except for Kenacort Retard,
which was purchased from Bristol-Myers Squibb (Paris,
France).
Culture of bovine retinal endothelial cells and treatments:
Bovine retinal endothelial cells (BRECs) were seeded in
Dulbecco’s modified Minimal Essential Medium (DMEM)/
glutamax supplemented with 10% calf serum and 20 ng of
VEGF (Sigma, St. Louis, MO), at 37 °C in a humidified
atmosphere containing 5% CO2. After 24 h the cells were
treated for either 24, 72 h, or 5 days with 0.1 or 1 mg/ml TA
that had been dissolved in 1% ethanol (TA-E; 99.9% ethyl
alcohol; VWR, Paris, France). Control cells were either not
treated or treated with 1% ethanol in medium. Before
treatment, cells were maintained in medium supplemented
with 2% of fetal calf serum (FCS) for 24 h. For treatment, cells
were cultured in medium supplemented with 2% FCS without
VEGF. In some experiments, cells were treated after
confluence was reached.
Analysis of TA effects on cultured cells:
Cell viability evaluation using MTT test—Viability
was assessed by the tetrazolium 3-(4,5-dimethylthiazol-2-
yl)-2,5 phenyltetrazolium bromide test (MTT; Sigma
Chemical) using 2.105 cells per well in 24-well plates. Briefly,
culture medium was removed and 250 µl of MTT (1 mg/ml
in 1× PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4, pH 7.4) were added to each well. The wells
were then incubated for 1 h at 37 °C, lysed with 250 µl of
isopropanol, and assessed by measuring absorption at 570 nm
versus 630 nm using a microplate reader (BioRad, San Diego,
CA). Using a standard curve for each experiment, we
correlated the color intensity observed in each well to the
number of viable cells assessed by the trypan blue exclusion
assay.
Evaluation of TA-induced viability reduction: lactate
dehydrogenase cytotoxicity assay In 24-well plates, 2.105
BRECs/well were treated with TA-E for 24 h, 72 h, or five
days. Released lactate dehydrogenase (LDH) in culture
supernatants was measured with a cytotoxicity detection kit
(Roche Diagnostics, Mannheim, Germany). Dye absorbance
was measured at 490 nm versus 630 nm using a standard
microplate reader. Positive control was obtained by the
complete lysis of control wells with 0.2% Triton X100.
Because treatment of BRECs with TA-E at 1 mg/ml induced
mostly necrosis, resulting from the direct contact of the
unsolved crystals with the cells, all further analysis were only
performed with TA-E at 0.1 mg/ml.
Evaluation of cell proliferation measuring DNA synthesis
rate: For proliferation assay, TA was used at 0.1 mg/ml and
0.5 μg/ml. BRECs (105 cells/well) were seeded in 24-well cell
culture plates and allowed to attach for 24 h. Thereafter, the
cells were incubated with TA-E for 24 h and 5-bromo-2-
deoxyuridine (BrdU) was added into the medium, for a final
concentration of 10 µM, and allowed to incubate for 18 h. The
incorporation of BrdU into the genomic DNA was determined
using the ELISA BrdU labeling and detection Kit III (Roche
Molecular Biochemicals, Germany).
For other experiments, BRECs were seeded at 5x104
cells/well in the Lab-Tek chambered Coverglass and grown
at 37 °C in a humidified atmosphere containing 5% CO2 and
95% air for 24 h. They were then treated with 0.1 mg/ml TA-
E, which is a concentration that allows further analysis.
Control cells were run using the culture medium alone or the
culture medium containing 1% ethanol. All experiments were
performed in triplicates and repeated twice. The Lab-Tek
slides were mounted in Gel Mount (Biomeda, Burlingame,
CA) before they were examined and photographed using an
Olympus IX70 fluorescent microscope coupled to a digital
camera. The following excitation/emission wavelengths were
used: 365–420 nm; 470/510 nm; 510/560 nm.
Detection of apoptosis using terminal deoxynucleotidyl
transferase dUTP nick end labeling assay: After treatment
with 0.1 mg/ml TA-E for 24 h, 72 h, or five days, the cells
were rinsed, air-dried, and fixed with 4% paraformaldehyde
(Merck Eurolab, Fontenay sous-bois, France) one hour at
room temperature. The cells were rinsed during 5 min in PBS,
and permeabilized with 0.3% Triton X-100 in PBS for 20 min.
Cells were incubated for 30 min with 50 µl of terminal
deoxynucleotidyl transferase dUTP nick end labeling assay
(TUNEL; Roche Diagnostics, Mannheim, Germany) reaction
mixture at 37 °C. The cells were then rinsed once with PBS,
stained with DAPI (Sigma), and rinsed with PBS five times
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for 5 min each time. Positive controls were obtained by
inducing apoptosis with 1 µM staurosporine.
Annexin V binding: Annexin V binding was assayed with the
Annexin V Apoptosis detection kit (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) according to the
manufacturer instructions. Briefly, after treatment cells were
rinsed with PBS, washed once for 5 min with 500 µl per well
of assay buffer and incubated 15 min at room temperature with
2 µg/ml of Fluorescein isothiocyanate (FITC)–labeled
Annexin V. Cells were then, rinsed with PBS, fixed with 4%
paraformaldehyde, rinsed with PBS, stained with DAPI and
rinsed five more times for 5 min with PBS.
Western blot analysis: Total protein extracts were obtained by
lysis of BRECs in Laemmli sample buffer. Extracted proteins
were separated by SDS–PAGE, immobilized on
nitrocellulose membrane (Millipore, Billerica, MA) and
blotted with affinity purified rabbit anti-active Caspase-3
polyclonal antibody in a 1:500 dilution (Calbiochem, San
Diego, CA). The secondary goat anti-rabbit IgG (Vector
Laboratories, Burlingame, CA) was used in a 1:5,000 dilution.
The amount of total protein extracts analyzed was 30 μg/lane.
Positive controls for caspase-3 activation were run on HL-60
cells, cultured in RPMI 1640 supplemented with 10%. Fetal
calf serum, treated for 24 h with 50 μM etoposide [19].
Immunocytochemistry: After the different treatments BREC
cells were stained with the following antibodies: anti-
cytochrome C [20] (Sigma, Steinheim, Germany) diluted
1:250 in PBS containing 1% BSA (BSA 98%; Sigma,
Steinheim, Germany); anti-apoptosis-inducing factor (AIF)
[21] (Sigma, Saint-Quentin Fallavier, France) diluted 1:100
in PBS containing 1% BSA; anti-microtubules-associated
protein and light chain 3 (MAP-LC3) [22] (Santa Cruz
Biotechnology) diluted 1:50 in PBS containing 1% fat-free
milk; and polyclonal anti- L -DNase II antibody [23,24]
TABLE 1. PRIMERS USED IN QPCR.
Name Sequence (5′-3′)
18S sense TGCAATTATTCCCCATGAACG
18S antisense GCTTATGACCCGCACTTACTGG
VEGF sense TGGGATGGTCCTTGCCTC
VEGF antisense TCGCTGGAGTACACG GTGGT
COX2 sense TGCTACCATCTGGCTTCGGGAG
COX2 antisense ACCCCTCAGGTGTTGCACGT
Figure 1. Effect of triamcinolone
acetonide on BRECs viability and
proliferation. Cell viability was
evaluated using an MTT assay.
Subconfluent (A) or confluent BRECs
(B) were exposed to 0.1 or 1 mg/ml TA
in 1% ethanol for 24 h (dark-gray
columns), 72 h (red columns), or five
days (white columns). Control cells
were either exposed to 1% ethanol (C-
E) or were left untreated (C). C: Cell
proliferation was evaluated using BrdU
labeling detection after 24 h of treatment
with 0.1 mg/ml or 0.5 µg/ml TA.
Control cells were either left untreated
(C) or were treated with 1% ethanol
(C-E). Results are expressed as mean
±standard error; with *p<0.05 for all
columns versus control. Four animals
were used in each experiment. DAPI
staining of untreated control cells are
shown in (D), 0.1 mg/ml TA-treated
cells in (E) and 1 mg/ml TA-treated cells
in (F), all of them after five days of
treatment. Scale bar represents 50 µm.
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diluted 1:100 in PBS containing 1% skimmed milk. After
incubation with the specific primary antibodies, the cells were
rinsed three times for 5 min with PBS, and incubated for 1 h
with goat Alexa Fluor anti-rabbit IgG (Molecular Probe
Invitrogen, NewYork, NY), or rabbit anti goat Texas red dye-
conjugated (Jackson Immuno Research Laboratories Inc.,
Suffolk, UK) diluted 1:250 in PBS containing 1% BSA. PBS
containing 1% BSA or 1% skimmed milk was used instead of
the primary antibody as negative controls.
For autophagic positive controls, BRECs were cultured
for 24 h in amino acid-depleted medium, e.g Hanks Buffered
Salt Saline (HBSS, Gibco, New York, NY) complemented
with 20 mM glucose [25]. Slides were mounted in Gel Mount
and examined with a fluorescent microscope Olympus IX70
coupled to a digital camera. The following excitation/
emission wavelengths were used: 365–420 nm; 470/510 nm;
510/560 nm.
Semithin and ultrathin structure analysis: Lewis rats used in
this study were obtained from Roger Janvier, Le Genest Saint
Isle, France. The use of animals adhered to the ARVO
statement for Ophthalmic and Vision Research and protocols
were approved by the ethical committee of René Descartes
University of Paris. Lewis rats (6-week-old, weighing 150 g)
were intravitreally injected with either 10 μl of PBS (n=3) or
with 10 μl of PBS containing 40 μg of TA (n=3). Thirty days
after injection, the rats were euthanized with a CO2 overdose,
and their eyes processed for semithin and transmission
electron microscopy analysis. The eyes were fixed in 2.5%
glutaraldehyde cacodylate buffer (Na 0.1 M, pH 7.4) for 1 h.
They were then dissected, and the posterior segments were
fixed for 3 h. Specimens were fixed in 1% osmium tetroxyde
TABLE 2. LDH RELEASE
 % of cytotoxicity % of cytotoxicity % of cytotoxicity
Treatment 24 h p 72 h p 5 days p
TA 1 mg/ml 23.7 <0.05 23.4 <0.05 24.3 <0.05
TA 0.1 mg/ml 3.6 <0.05 4.24 <0.05 5.1 <0.05
C-E 0  0  0  
C 0  0  0  
Triton 0.2% 100  100  100  
Measure of LDH release in BRECs after 24 h, 72 h, and 5 days of treatment with 1 mg/ml or 0.1 mg/ml of TA. Control cells
were either not treated (C), 1% ethanol-treated (C-E ), or 0.2% triton-treated. No LDH release was found in control cells and a
small increase is seen in cells treated with 0.1mg/ml of TA. The use of 1 mg/ml of TA drastically increase LDH release.
Figure 2. Absence of TUNEL-positive
apoptosis in BRECs treated with
triamcinolone acetonide. Control cells
were treated with the TA vehicle,1%
ethanol, (A-C). No TUNEL-positive
cells could be observed after exposure
to 0.1 mg/ml TA for 72 h (D-F) or five
days (D5, G-I). As a positive control for
the TUNEL technique, BRECs were
treated with 1 μM staurosporine (J-L).
Nuclei were stained with DAPI (A, D,
G, J). Scale bar represents 60 µm.
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in cacodylate buffer (Na 0.1 M, pH 7.4) and progressively
dehydrated in graduated ethanol solution (50, 70, 95, and
100%). Each posterior segment was separated in two samples,
included in epoxy resin and oriented. Sections were cut to
1 µm thickness with an ultra microtome Reichert Ultracut
(Leica, Biel, Switzerland) and stained with toluidine blue.
Sections cut to 80 nm thick were stained by uranyl acetate and
lead citrate, and analyzed with a Philips CM10 electron
microscope.
Vascular corrosion casts: Lewis rats (12, 8-week-old,
weighing 150 g) were intravitreally injected with either 10 µl
of PBS (n=6) or with 10 µl PBS containing 40 µg of TA (n=6).
After 30 days the animals were sacrificed by CO2 inhalation
followed by a thoracotomy. A catheter was introduced into
the aorta through the left heart ventricle, and the right auricle
was cut to allow evacuation of injected products. A perfusion
was performed with a mixture of red Mercox resin and catalyst
(Ladd Research, Williston, VT). Eyes were extracted and
lenses were removed. Tissues were conserved overnight at
37 °C in PBS to allow complete polymerization, and then
digested by 5% KOH for two weeks at 37 °C until only the
vascular corrosion casts remained. Distilled water was used
to remove salt, and the mold was dried. Only corrosion casts
with completely filled iris vessels were used. This was to
exclude corrosion casts from incomplete perfusion. Retinal
vasculature was removed with forceps. The specimens were
mounted on Stretched Specimen Mount (SSM) stubs, coated
with gold palladium, and scanned at an accelerating voltage
of 117 kV. To measure the thickness of the choriocapillary
lumen, we cut corrosion casts paracentrally (1 mm from the
aperture of the optic nerve) and positioned for perpendicular
views of the choriocapillaries. To analyze the intercapillary
space (avascular area), we positioned the casts for frontal
views of the choriocapillaries. Electron micrographs were
Figure 3. Annexin V binding of TA treated BRECs. Annexin-V binding was performed in control cells, treated with 1% ethanol (the TA
vehicle; A-C) or with 0.1% TA for 72 h (D-F) or five days (G-I). Condensed nuclei are seen in TA treated cells (D and G, squares) as well
as Annexin-V positive cells (E and H, squares). Arrows indicates Annexin-V positive cells. Scale bar represents 50 µm.
Molecular Vision 2009; 15:2634-2648 <http://www.molvis.org/molvis/v15/a281> © 2009 Molecular Vision
2638
scanned and analyzed using Image J Software. The avascular
areas were measured on frontal views and expressed as the
percentage of intercapillary surface (space between the plastic
capillary casts) of the whole area (n=6 rats; five pictures/cast).
Effect of TA on VEGF and COX-2 expression in primary
retinal pigment epithelium (RPE) cells:
Rat RPE primary culture—Ten-day-old Wistar rat
pups were sacrificed by CO2 inhalation and the eyes were
enucleated. Eyes were maintained at room temperature
overnight in DMEM (Invitrogen, Cergy Pontoise, France)
then incubated 45 min with 2 mg/ml trypsin/collagenase I at
37 °C. After trypsin inhibition with DMEM containing 10%
FCS, the RPE layer was harvested. The RPE was plated in 12-
well plates at a rate of one RPE from one eye per well in
DMEM containing 10% FCS, 1% penicillin/streptomycin,
and 0.2% fungizone. Cells were maintained for 12 days before
the phagocytosis assay [26].
Outer segments isolation and phagocytosis assay: Outer
segments (OS) were isolated following established protocols
[27]. Briefly, 20 pig retinas were dissected and homogenized
in 20% sucrose buffer, 20 mM Tris, 2 mM MgCl2, and
0.13 mM NaCl (pH 7.2). Retina samples were centrifuged on
a sucrose gradient (50%, 27%) 1h at 100,000× g, and OS were
harvested at the ring interface and diluted in DMEM.
Centrifugation for 10 min at 10,000× g was performed, and
the pellet was resuspended in DMEM to obtain a stock
solution of 108 OS/ml.
Before treatment, RPE cells were maintained in medium
supplemented with 2% of FCS for 24 h. Confluent rat primary
RPE cells were incubated with 0.1 mg/ml TA-E. Control cells
were run using the culture medium alone. After 24 h of
treatment, the cells were rinsed once with PBS and incubated
with 150 μl of 108 outer segments/ml. After 1 h, 850 µl of
complete medium was added. After 6 h, cells were washed
and 350 μl of guanidine thiocyanate lysis buffer (RNeasy mini
kit; Qiagen, Courtaboeuf, France) was added for RNA
extraction.
Reverse transcription and real-time polymerase chain
reaction: Total RNA was isolated with RNeasy plus Mini Kit
(Qiagen, Courtaboeuf, France). Single-stranded cDNA was
synthesized from total RNA using random primer and
superscript reverse transcriptase (Invitrogen). Subsequent
real-time polymerase chain reaction (RT–PCR) was
performed using cDNA, qPCR SuperMix-UDG Platinum
SYBR Green (Invitrogen), and the and 0.5 pmol/µl of the
primers described on Table 1.
PCR reactions were performed in 40 cycles of 15 s at
95 °C, 45 s at 60 °C. No product was obtained in control
reactions where reverse transcriptase was omitted.
Statistical analysis: Data are represented as mean±standard
error of the mean (SEM) and compared using the
nonparametric Mann–Whitney U test. P values were
calculated for a confidence interval of 95% and p values of
less than 0.05 were considered significant.
RESULTS
Effect of TA on BREC viability: The percentage of living cells
was reduced to 75±1.1%, p<0.05 after exposure to 0.1 mg/ml
of TA for 24 h. This survival was reduce to 52±2.9% p<0.05
as concentration of TA increased to 1 mg/ml. The rate of
survival was further reduced as exposure time increased,
being of 58±2.3% and 50±3.7% for 0.1 mg/ml, and 1mg/ml
of TA, respectively, after 72 h and of 55±2% and 39±0.9%
p<0.05, respectively, for the same concentrations after 5 days
of treatment. TA therefore decreased the number of living
cells as compared to control cells, with an increased effect
upon exposure duration. Photomicrographs of DAPI-stained
BREC nuclei in culture showed that after 72 h (not shown) or
five days (Figure 1D-F) of treatment with 0.1 mg/ml TA-E,
the cells were not only reduced in number (Figure 1D), but
also organized in a ramified manner (Figure 1E). After
treatment with 1 mg/ml for 72 h or five days (Figure 1F), the
number of cells was reduced and many cellular debris were
present in the culture medium. To evaluate whether the
reduction in the number of living cells resulted from a
reduction in proliferation or in TA-induced cell toxicity, we
performed the same experiments on confluent cells. As shown
on Figure 1B, TA induced a similar reduction in the number
of living cells, this effect increased upon the duration of
exposure and the concentration, suggesting that the reduction
Figure 4. Caspase 3 western-blot
analysis. As a positive control HL-60
cells were treated with etoposide (Eto).
The cleaved, active form of caspase 3 is
seen. Expression of pro-caspase 3 is
seen en BRECs in all conditions. No
expression of activated caspase 3 was
detected in any of the treated BRECs,
demonstrating that triamcinolone
acetonide (TA) did not induce caspase 3
activation.
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in the number of living cells did not result solely from an
inhibition of cell proliferation.
Inhibition of BREC proliferation: To further characterize the
effect of TA on endothelial cell proliferation, we evaluated
the DNA synthesis rate using the BrdU test. As shown in
Figure 1C, 0.1 mg/ml TA-E significantly reduced the
proliferation rate of BRECs from OD=2.06±0.09 in control
cells to OD=1.62±0.02, n=4, *p<0.05 in TA-E treated cells.
This effect was not observed with a lower concentration of
TA-E: 0.5 µg/ml (OD=1.8±0.03).
Evaluation of retinal endothelial cell death after exposure to
TA:
Necrosis in BREC exposed to TA: Measurement of
LDH release The reduction in the number of living cells could
not be explained only by a decrease of proliferation.
Therefore, cell death mechanisms were explored. We first
measured the amount of free LDH as a marker of passive cell
death (e.g., necrosis; Table 2). LDH is a cytoplasmic enzyme
not released during active cell death like apoptosis, paraptosis,
or autophagy, but released in necrosis due to the early increase
of plasma membrane permeabilization. No necrosis was
observed in control cells; exposure of BRECs to 1 mg/ml TA-
E induced necrosis in 23.7% of the cells after 24 h of exposure,
in 23.4% after 72 h, and in 24.3% of the cells after five days
(p<0.05). After exposure to 0.1 mg/ml TA-E, a significantly
lower release of LDH than before was observed, reaching
3.6% after 24 h, 4.2% after 72 h and 5.1% after five days of
treatment (p<0.05). Taking into account the inhibition of
proliferation and the percentage of necrosis occurring in
0.1 mg/ml TA-E treated cells; it is possible there is another
type of cell death that could possibly explain the reduced
number of living cells after 72 h and five days.
When 1 mg/ml TA was dissolved in 1% ethanol, crystals
remained undissolved and stayed adherent to the cell
membranes, resulting in the direct cytotoxic observed effects.
Therefore, for further analysis, only cells treated with 0.1 mg/
ml TA-E were used. Since the TA effect on cell viability was
Figure 5. Cytochrome C release in TA treated BRECs. Absence of cytochrome C release in triamcinolone acetonide (TA)-treated BRECs.
Control cells are shown in A to C. TA treated cells for 72 h are shown in D to F and for 5 days in G to I. No cytochrome C release is seen in
these cells. Compare to cells treated with staurosporin (Stp) used as positive control (J-L, arrow in K and L). Nuclei were stained with DAPI
(A, D, G, J). Scale bar represents 50 µm.
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increased with the time of treatment, cell death was analyzed
after 72 h and five days of exposure.
Caspase-dependent apoptosis: Caspase-dependent apoptosis
was evaluated by TUNEL assay, annexin-V binding, caspase
3 activation, and cytochrome C release. As shown in Figure
2, no TUNEL-positive cells were detected after treatment with
1% ethanol (Figure 2A-C). In addition, no TUNEL-positive
cells could be detected in cells treated with 0.1 mg/ml TA-E
after 72 h (Figure 2D-F) or even after five days of exposure
(Figure 2G-I). However, when cells were exposed to 1 µM
staurosporine, a known inducer of caspase-dependent cell
death, TUNEL-positive cells with condensed nuclei were
observed (Figure 2J-L).
During the early phases of any type of apoptosis,
phosphatidyl serine translocates to the external surface
membrane of the cell [28] and binds annexin-V [29]. As
shown in Figure 3, while no annexin V was found to bind on
the surface of control cells (Figure 3A-C), positive, stained
cells were detected after 72 h and five days of exposure with
0.1 mg/ml TA-E (Figure 3D-F,G-I). After 72 h of exposure to
TA, annexin-V positive cells displayed condensed or
fragmented nuclei (Figure 3D-F insets), while after five days
some cells displaying normal (uncondensed) nuclei also
started annexin-V binding (Figure 3G-I insets).
The results discussed in the previous section suggested
the activation of apoptosis with no activation of caspase. To
assess this point, we performed western blot analysis of
caspase-3 activation. The results obtained revealed the
presence of pro-caspase-3 and the absence of activated
caspase-3 in BRECs treated during 72 h or five days with
either nothing, 1% ethanol medium, or in 0.1 mg/ml TA
(Figure 4). In positive control HL-60 cells treated with
etoposide, pro-caspase-3 as well as activated caspase-3 were
detected (Figure 4). These experiments showed that a
noncaspase dependent form of apoptosis could intervene.
After a toxic stress caspase 3 is, in most of the cases,
activated though the intrinsic pathway, in which, the release
of cytochorme C from the mitochondria is a key event. We
investigated then if cytochrome C was released. In BRECs
treated during 72 h or five days with 0.1 mg/ml of TA-E
Figure 6. L-DNase II activation in TA treated BRECs. LEI/L-DNase II immuno-labeling was performed in control cells treated with the TA
vehicle (1% ethanol). A-C: A cytoplasmic labeling is seen. In cells treated with 0.1 mg/ml TA for 72h (D-F) or 5 days (G-I), cells with
condensed nuclei (arrows) present a nuclear staining for LEI/L-DNase II, indicating L-DNase II activation. Nuclei were stained with DAPI
(A, D, G). Scale bar represents 50 µm.
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(Figure 5D-F,G-I), no release of cytochrome C from
mitochondria into the cytoplasm could be observed. The
fluorescent labeling appeared indeed located in mitochondria,
and no diffuse or nuclear fluorescence was present, indicating
that mitochondria have not released cytochrome C. In
contrast, in BRECs treated with staurosporine, cytochrome C
was located in condensed nuclei of apoptotic cells (Figure 5
J-L, arrows).
Caspase-independent apoptosis in triamcinolone acetonide-
induced toxicity: As the cell death induced by TA seemed to
be caspase independent, we analyzed two markers of caspase-
independent apoptosis in TA-treated BRECs: leukocyte
elastase inhibitor/ L-DNase II (LEI/L-DNase II) and apoptosis
inducing factor (AIF).
LEI and L-DNase II are two forms of one protein that are
recognized by the same antibody. However, while LEI is a
cytoplasmic anti-protease, its nuclear translocation parallels
its change into L-DNase II activity [30]. While LEI/L-DNase
II fluorescent labeling was present in the cytoplasm of the
control cells (Figure 6A-C), surrounding non-fluorescent
nuclear shapes, a clear nuclear staining was observed in cells
treated with 0.1 mg/ml TA for 72 h or for five days (Figure
6D-F,G-I, arrows). Nuclei positive for L-DNase II were
condensed or fragmented, indicating a caspase-independent
apoptotic pathway, taking place in BRECs cells treated with
TA.
In control cells (Figure 7A-C), anti-AIF showed a
cytoplasmic labeling; corresponding to the normal
localization of AIF at the mitochondria. After 72 h of TA-E
treatment no change in AIF localization was seen (Figure 7D-
F). However, after exposure to 0.1 mg/ml TA-E for 5 days,
some cells with condensed or fragmented nuclei showed
positive nuclear staining. This suggested that caspase-
independent apoptotic pathways were activated in TA-treated
cells (Figure 7G-I, arrows).
Autophagy: After activation of autophagy, MAP-LC3
concentrated in autophagic vesicles, giving a dotted pattern to
the cells. After 72 h (not shown) or five days of treatment with
0.1 mg/ml TA-E (Figure 8D-F), no MAP-LC3-positive
vesicles could be observed—meaning that autophagy was not
Figure 7. Apoptosis Inducing Factor localization in triamcinolone acetonide treated BRECs. Apoptosis inducing factor (AIF) immuno-labeling
was performed in control cells treated with the TA vehicle (1% ethanol; A-C). A cytoplasmic labeling is seen. This is also the case in cells
treated with 0.1 mg/ml TA for 72h (D-F). In cells treated with TA for 5 days (G-I), cells with condensed nuclei (arrows in H and I) present
a nuclear staining for AIF. Nuclei were stained with DAPI (A, D, G). Scale bar represents 50 µm.
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taking place under these conditions. In cells cultured in amino
acid-deprived medium, a condition known to induce
authophagy, cells showed large intracytoplasmic vesicles that
stained positive with anti-MAP-LC3 antibody (Figure 8G-I).
Structural analysis of rat retinal and choroidal vasculature,
one month after TA exposure: As demonstrated, the results
obtained indicated that TA could affect endothelial cell
viability. We investigated this hypothesis in vivo. Semithin
analysis of the retina did not show evidence of alteration of
the retinal vessels or capillaries, but did show that a reduction
of the diameter of the superficial capillaries was evident on
sections of TA-treated retinas (Figure 9B) versus control ones
(Figure 9A). More striking was the significant thinning of the
choriocapillaries and choroid in the TA-treated rats (Figure
9D) as compared to PBS-injected rats (Figure 9 C and E).
Moreover, as previously described [26] in TA-treated rats,
there were alterations of the outer segments and vacuolization
of the RPE cells (Figure 9D stars).
Analysis of rat choroidal vascular corrosion casts one month
after TA exposure: To better analyze and quantify the
modifications observed in the choroidal vascular network, we
performed resin casts. In rats exposed to TA for a month, the
casts showed that the spaces between choriocapillaries were
increased and that capillary diameter was reduced as
compared to PBS-injected rats. Figure 10A,B presents frontal
views of choriocapillary casts of a PBS-treated rat and a TA-
treated rat. Figure 10C,D shows cross-sectional cuts of
pericentral choroidal corrosion casts of a PBS-treated rat and
a TA-treated rat. In the TA-treated rat eyes, the avascular areas
between choriocapillaries were significantly increased (n=6,
*p<0.05 versus PBS) and the choriocapillary diameter
significantly reduced (n=6, *p<0.05 versus PBS; Figure
10E,F).
Modulation of VEGF and COX-2 expression in RPE cells
exposed to OS phagocytosis: To explore a potential indirect
mechanism responsible for TA-induced choriocapillaries
alterations, we evaluated whether the expression of cyclo-
oxygenase-2 (COX-2) and VEGF in RPE cells submitted to
OS phagocytosis was modulated by TA exposure. We have
previously shown that COX-2 knockout mice develop
significant choriocapillary involution [26]. So we hypothesed
Figure 8. Evaluation of autophagy by microtubules-associated protein light chain 3 staining. No intracytoplasmic vacuoles were stained with
anti-microtubules-associated protein light chain 3 (MAP-LC3) in control BRECs (A-C). This is also the case for BRECs exposed to 0.1 mg/
ml TA for five days (D-F). In the amino acid (AA) deprived medium (positive control), BRECs show multiple MAP-LC3 positive cytoplasmic
vacuoles (G-I, arrows in I). Nuclei were stained with DAPI (A, D, G). Scale bar represents 50 µm.
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that beside a direct toxic effect of TA, COX-2 downregulation
could also be induced by TA on the choriocapillary in vivo.
In primary culture rat RPE cells, OS phagocytosis
significantly enhanced COX-2 expression (Figure 11A;
***p<0,001, OS versus control). TA decreased significantly
the expression of COX-2 under basal condition (Figure 11A;
*p<0.05 versus control) and also significantly reduced the OS
phagocytosis-induced COX-2 upregulation (*p<0.05 OS-TA
versus OS). Interestingly, while TA also significantly
downregulated basal VEGF expression (Figure 11B; *p<0.05
TA versus control), it did not influence OS phagocytosis-
induced VEGF upregulation (Figure 11B; ***p<0.001 OS
versus control).
DISCUSSION
Glucocorticoids are known to induce vascular effects. The
McKenzie test, based on skin bleaching, has been the basis for
the classification of glucocorticoid potency and cutaneous
absorption [31]. This test uses the visual quantification of the
skin whitening after 8 to 48 h of exposure to different
glucocorticoids applied topically and under occlusion.
Although this test is widely used, the exact mechanism of skin
whitening remains unknown and unexplored. The effects of
steroids on growing vessels have been described by Folkman
and Ingber [32]. They showed that only a low dose of
dexamethasone (0.2 µg/µl) or hydrocortisone (5–6 µg/ml)
could induce the regression and prevent the growth of
Figure 9. Semithin analysis of the retina-
choroid. At 30 days after triamcinolone
acetonide (TA) injection, the diameter
of retinal vessels was reduced as
compared to control PBS injected eyes
(B, A, respectively, arrows). The
thickness of the choroids was
significantly reduced in TA-treated (D)
as compared to the control eye (C and
E). Vacuoles were observed in retinal
pigment epithelial (RPE) cells and outer
segment in the TA-treated eyes (D,
stars). Results are expressed as mean
±standard error, with ***p<0.001.
Fours animals were used in this study.
Abbreviations: outer nuclear layer
(ONL), inner segment (IS), outer
segment (OS). Scale bar represents 20
µm.
Figure 10. Choroidal vascular casts.
Frontal view of choroidal casts showed
that 30 days after injection of
triamcinolone acetonide (TA), the
avascular areas were increased (B, red
double-headed arrow) as compared to
the control PBS-treated eyes (A). Cross-
sectional cuts of pericentral choroidal
corrosion cast (C, D) showed a reduced
thickness of the choriocapillaries in TA-
treated eyes. Scale bar represents 10 µm.
E: Quantification of the avascular areas
in the choriocapillaries confirmed a
significant increase in TA-treated eyes,
and (F) mean vessel diameter was
significantly reduced. Results are
expressed as mean±standard error with
*p<0.05 when consideringTA versus
PBS. Six animals were used in this
study.
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neovessels in the chorioallantoid membrane. High doses, over
10 µg/ml, were toxic. Folkman experiments with chemically
modified steroids demonstrated that the vascular effect was
not related to the corticosteroid activity but to their effect on
the basal membrane of growing vessels. Further studies show
that steroids inhibit human endothelial cells proliferation
[33], or promote human dermal microvascular cells [34], these
effects depending on the type of steroid, the doses and the
duration of exposure [35].
In many ocular models of angiogenesis and of human
pathologies, the growth of neovessels takes place in a complex
wound healing process, where inflammation and angiogenesis
are closely interlinked [36]. Therefore, the effects of
glucocorticoids result from both a strong anti-inflammatory
activity and a direct but unclear effect on vessels.
In vitro experiments performed in our study allowed us
to analyze the direct effect of TA on BRECs. We have
demonstrated that the effects of TA depend on both the TA
Figure 11. COX-2 and VEGF mRNA expression in RPE cells treated
with TA. COX-2 (A) and VEGF (B) mRNA expression (real time
quantitative PCR) in untreated control primary rat RPE cells (C), or
in RPE cells exposed to triamcinolone acetonide (TA), outer
segments (OS) or both (OS-TA). Results are expressed as mean
±standard error with *p<0.05, ***p<0.001, when considering all
columns versus control in (B) and in (A) *p<0.05 OS-TA versus OS.
Four animals were used in each study.
solubility and the duration of exposure. At 1 mg/ml, TA did
not dissolve completely in ethanol 1%, and the observed
necrosis was due to the direct contact of crystals with the
cultured cells as previously observed with RPE and rat Müller
glial (RMG) cells [25]. When confluent cells were exposed to
0.1 mg/ml TA-E, a clear decrease in the number of living cells
was observed, which resulted from noncaspase-dependent
apoptotic pathways. Similarly Hartnett et al. found that TA
induced a dose-dependent toxic effect on human retinal
microvascular endothelial cells, without any activation of the
caspase-3 [15], suggesting that noncaspase-dependent
apoptotic pathways could be activated.
In our experiments, LEI/L-DNase II was associated with
apoptosis of BRECs after 72 h of TA exposure. This is an
important result because this enzyme produces 3′P ends [37]
in DNA, a break that is not labeled by terminal transferase.
This explains why theses cells showing apoptotic morphology
and Annexin V staining remain TUNEL negatives. Moreover,
as this is the regular technique used to evaluate the induction
of cell death in a tissue, many dying cells remain unrevealed.
In addition to LEI/L-DNase II, AIF is also nuclearized,
suggesting that it is involved in the death of cells after 5 days
of TA exposure. So that, multiple caspase-independent
mechanisms may mediate this cell death [38]. Despite an
abundant literature on the anti-angiogenic activity of steroids,
this is to our knowledge, the first study to analyze the
mechanisms of TA-induced endothelial cell death. At low
dose (1 µM), TA did not influence BREC proliferation, while
a moderate effect on cell proliferation was observed at the
dose of 0.1 mg/ml, confirming the dose-dependence of
endothelial cell proliferation..
The more striking observation was that after intravitreous
injection, TA also induced vascular changes, mostly at the
level of the choroids. We could not measure precisely in vivo
whether TA induced any changes in retinal vessel diameter as
demonstrated in patients [39], but our histological analysis
seemed to confirm a potential effect of TA on superficial
retinal capillary diameter. However, no striking effects on the
retinal vessel structure were observed. Moreover, using both
semithin and ultrathin analysis and choroidal casts, we could
observe a reduction in the choroidal thickness, a rarefaction
of cells in the choroids, and a rarefaction of choriocapillaries
with increased spaces between the capillaries. At this stage, it
is not possible to determine whether the increased space
between capillaries results from a loss of capillaries or a
vasoconstriction of the vessels. Further studies are undertaken
to evaluate potential toxic effect of TA on resting versus
proliferating choroidal neovessels.
Interestingly, endothelial cell damage has been reported
in veins of rabbits treated with 4 mg/kg methylprednisolone
acetate for four weeks. They show ultrastructural alterations
of endothelial cells and pericytes [40] suggesting that in vivo
steroids may be toxic for the vasculature. This observation is
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in agreement with the superficial skin ecchymoses known to
occur after long-term corticotherapy [41]. Finally, Blaha et al.
described the occurrence of profound choroidal
hypoperfusion in patients treated with combined
photodynamic therapy and intravitreous injections of
triamcinolone [42]. It remains to be determined if this
complication is related to the direct potential effect of TA.
The relative selective effect of TA on the
choriocapillaries as compared to the retinal vasculature in
vivo may result from different factors. First, the
choriocapillary endothelium is fenestrated and much less
protected than retinal capillaries, which are surrounded by
pericytes, astrocytes, and retinal Müller glial cells. So that, the
choriocapillary endothelium may be more exposed to TA
toxicity than the retinal endothelium. Aside from a direct toxic
effect, TA could exert an indirect effect through the
downregulation of COX2 in RPE cells. In a previous study,
we indeed demonstrated that CD36 −/− mice that produce
reduced COX-2 levels in RPE cells develop a progressive
choriocapillary involution. The activation of COX-2, induced
by OS phagocytosis could be important in the homeostasis of
choriocapillaries [26]. Interestingly, in our experiments, while
TA in vitro prevented the upregulation of COX2 under OS
phagocytosis, it did not affect VEGF upregulation. Whether
other pro angiogenic factors are downregulated downstream
COX2 in RPE cells will be investigated.
Other pro angiogenic factors could be downregulated
downstream of COX-2 in RPE cells. Moreover, when
angiogenesis develops in the choriocapillaries, as in age-
related macular degeneration, the anti-inflammatory and anti-
proliferative effects of TA may be involved in its antivascular
effects [13]. These issues will be matters for future
investigation.
In conclusion, this is the first study to demonstrate that
glucocorticoids induce direct retinal endothelial cells toxicity
through noncaspase apoptotic pathways involving LEI/ L-
DNase II and AIF. While long-term exposure to TA did not
induce any detectable toxicity for retinal vessels in vivo, it did
lead to choriocapillary rarefaction. Taking into account that
those changes may occur without any inflammatory reaction,
in the long term, they may be overlooked in clinical practice
and induce deleterious consequences on visual acuity.
However, because Lewis rats are albinos, and because the rat
retina differs from the human retina, no direct extrapolation
can be made regarding toxicity in patients. This study is an
indication that triamcinolone may exert some effects on the
choroidal vessels and that this parameter should be monitored
particularly in patients with preexisting chorioretinal
pathologies. The effects of TA injected in the suprachoroidal
space of pigmented rats are currently under investigation to
complete the present study. Further studies should be
undertaken to characterize precisely whether choriocapillary
changes occur in patients treated with repeated intravitreous
injections of TA.
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